A Human Controlled Infection Study with Neisseria Lactamica in Malian Adults

NCT ID: NCT04665791

Last Updated: 2025-03-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 55 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-03-02
• Study Completion Date: 2023-06-06

Brief Summary

This study is part of a series of projects to improve protection against meningitis. Previously, researchers have given nose drops containing N. lactamica to over 400 volunteers and shown that many of them become colonised with N. lactamica without causing any illness or disease. This has previously been shown to prevent people from becoming colonised with N. meningitidis which can cause meningitis. This study aims to give nose drops containing N. lactamica to healthy adults in Mali, to see if they become safely colonised. In the future the study team would like to find out how N.lactamica helps children resist N.meningitidis, and develop new vaccines that exploit that mechanism.

Detailed Description

In this pilot research, the study team will use a methodology of nasal inoculation with reconstituted lyophilised N. lactamica (hereafter LyoNlac) developed in a previous, UK-based, human challenge study. This methodology and will be developed further and validated in healthy Malian adults.

A dose-ranging strategy will be used, starting with the dose identified as the standard inoculum in healthy adults in the UK, which was the dose required to induce colonisation in approximately 80% of volunteers. The dose will be escalated to a dose able to induce a similar level of colonisation in Malian adults. This study will inform the study team whether intranasal inoculation of reconstituted lyophilised Nlac (hereafter, lyoNlac), can result in immunising colonisation of adult Malian volunteers and the optimal dose to achieve this. This dose and methodology will then be used in future studies looking at the duration and immunogenicity of colonisation induced by LyoNlac in Mali.

Conditions

Meningitis, Meningococcal

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Challenge

Challenge participants will be inoculated intranasally with reconstituted, previously lyophilised Neisseria lactamica (LyoNlac). The initial dose will be 10\^5 colony forming units and will be escalated to a maximum of 10\^7 colony forming units to find the dose which successfully colonises at least 70% of volunteers.

Group Type: EXPERIMENTAL

Intranasal inoculation with Neisseria lactamica

Intervention Type: BIOLOGICAL

Lyophilised Neisseria lactamica will be reconstituted and administered to participants intranasally.

Interventions

Intranasal inoculation with Neisseria lactamica

Lyophilised Neisseria lactamica will be reconstituted and administered to participants intranasally.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Healthy adults aged 18 to 45 years inclusive on the day of enrolment residing outside the demographic surveillance area
• Able and willing (in the investigator's opinion) to understand and comply with all study requirements including availability for all study follow up visits
• Provide written informed consent to participate in the trial
• For females only, all the following:
• willingness to practice continuous effective contraception at least until the Day 28 visit is complete
• negative urine pregnancy test on the screening day
• negative urine pregnancy test on inoculation day

• Healthy adults aged 18 to 45 years inclusive on the day of enrolment residing outside the demographic surveillance area
• Able and willing (in the investigator's opinion) to understand and comply with all study requirements including availability for all study follow up visits
• Provide written informed consent to participate in the trial
• For females only, all the following:
• willingness to practice continuous effective contraception at least until the Day 28 visit is complete
• negative urine pregnancy test on the screening day
• negative urine pregnancy test on inoculation day

Exclusion Criteria

Eligibility Minimum Age: 18 Years Maximum Age: 45 Years Sex: All Gender Based: No Accepts Healthy Volunteers: Yes

• N. lactamica detected on throat swab taken at the screening visit
• Individuals who have an ongoing acute illness at the time of inoculation
• Individuals who have been involved in other clinical trials involving receipt of an investigational product over the last 12 weeks or if there is planned use of an investigational product during the study period
• Use of systemic antibiotics within the period 30 days prior to the challenge
• Any confirmed or suspected immunosuppressive or immune-deficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication (including oral steroids) within the past 6 months (topical steroids are allowed)
• Use of immunoglobulins or blood products within 3 months prior to enrolment.
• History of allergic disease or reactions to soya.
• Any clinically significant abnormal finding on clinical examination or screening investigations
• History of any surgery to the nose or throat in the previous 3 months
• Any other significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
• Occupational, household or intimate contact with immunosuppressed persons
• Positive pregnancy test or lactation

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Southampton

OTHER

Sponsor Role: collaborator

University of Maryland

OTHER

Sponsor Role: collaborator

University College, London

OTHER

Sponsor Role: collaborator

University of Oxford

OTHER

Sponsor Role: collaborator

Public Health England

OTHER_GOV

Sponsor Role: collaborator

Center for Vaccine Development - Mali

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Robert C Read, MD FRCP

Role: PRINCIPAL_INVESTIGATOR

University of Southampton

Samba Sow, MD

Role: PRINCIPAL_INVESTIGATOR

Center for Vaccine Development - Mali

Milagritos Tapia, MD

Role: PRINCIPAL_INVESTIGATOR

University of Maryland

Locations

CVD Mali

Bamako, , Mali

Countries

Mali

Other Identifiers

62190

Identifier Type: -

Identifier Source: org_study_id